|
Chief Editor
Having worked in the British, French and Swiss financial press, Romain is able to report on local and international issues, as comfortable in French as in the language of Shakespeare, Romain Fournier leads the editorial team at Marketscreener. Fine connoisseur of the English-speaking markets, Romain delivers an editorial every day on US and UK markets.
|
Every day, find a selection of analysts’ recommendations covering North America and the UK. The list only includes companies that have been the subject of a change of opinion or price target, or of a new coverage. It may be updated during the session. This information is used to shed light on the movements of certain stocks or the market sentiment on a company.
- Abbott Laboratories: BofA Securities reinstates at buy with $140 price target.
- Block: UBS adjusts block price target to $178 from $322, maintains buy rating
- Booking Holdings: Evercore ISI lifts to outperform from in-line, price target to $2,900 from $2,500
- Chevron: DZ Bank raised the recommendation to buy from hold. PT up 12% to $167.
- Croda: Jefferies maintains a hold rating with a price target reduced from GBp 8,000 to GBp 7,900.
- Flutter: JP Morgan remains Overweight with a reduced target of GBp 17,010 to GBp 15,990.
- Live Nation: Goldman Sachs adjusts price target for live nation entertainment to $145 from $130, maintains buy rating
- Mattel: UBS adjusts mattel price target to $35 from $28, maintains buy rating
- Medtronic: BofA Securities reinstates at buy with $135 price target.
- Mercantile Bank: Raymond James upgrades to strong buy from outperform. PT up 24% to $44.
- Progressive: Goldman Sachs downgrades to neutral from buy. PT up 12% to $116.
- Royal Mail: Liberum downgrades from hold to sell targeting GBp 355.
- Spectris: HSBC downgrades from buy to hold targeting GBp 2900.
- The Allstate Corporation: Goldman Sachs raised to buy from sell. PT up 18% to $142.
- Workday: UBS adjusts workday price target to $275 from $250, maintains buy rating
- Zoom Video Communications: JPMorgan lowers price target to $295 from $385, maintains overweight rating
MarketScreener.com 2022
Source link